AKT1 and cancer: Metformin is proven to hinder the proliferation of different types of cancer cells through its impact on glucose metabolism and the phosphatidylinositole-3 kinase-akstrain transforming-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway.